Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Oral Doses of Inno8 in Healthy Male Participants
Latest Information Update: 29 Oct 2024
At a glance
- Drugs Inno-8 (Primary) ; Inno-8 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms VOYAGER1
- Sponsors Novo Nordisk
- 29 Oct 2024 New trial record